ACUTE MYELOID-LEUKEMIA WITH T(911)(P22Q23) IN A PATIENT TREATED FOR ADULT T-CELL LEUKEMIA

被引：14

作者：

NAKAMURA, H ^{[1
]}

ISHIZAKI, T ^{[1
]}

ITOYAMA, T ^{[1
]}

SODA, H ^{[1
]}

YOSHIDA, Y ^{[1
]}

YAMADA, Y ^{[1
]}

KURIYAMA, K ^{[1
]}

SADAMORI, N ^{[1
]}

TOMONAGA, M ^{[1
]}

机构：

[1] NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT HAEMATOL,NAGASAKI,NAGASAKI 852,JAPAN

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1994年 / 86卷 / 01期

关键词：

AML; ADULT T-CELL LEUKEMIA; THERAPY-RELATED;

D O I：

10.1111/j.1365-2141.1994.tb03285.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 37-year-old male patient with adult T cell leukaemia (ATL) began receiving chemotherapy in March 1992. He achieved complete remission in May 1992, but developed acute myeloid leukaemia (AML, FAB subtype M2) with t(9;11)(p22;q23) in May 1993. The presence of chromosome 11 abnormality at band 11q23 in this patient suggests that the AML was related to the chemotherapy with etoposide for ATL. Furthermore, the combination of etoposide with two cytostatic drugs, cyclophosphamide and carboplatin, possibly induced the leukaemia early (14 months) after the start of chemotherapy. To our knowledge, is the first report of therapy-related AML after chemotherapy for ATL.

引用

页码：222 / 224

页数：3